WASHINGTON, May 15, 2026 —
The Supreme Court on Thursday indefinitely extended its freeze on new restrictions that would have required women to see a doctor in person before receiving the abortion pill mifepristone — keeping the drug accessible by mail and telehealth prescription for millions of Americans while a lawsuit filed by Louisiana works its way through the lower courts.
The unsigned majority order came roughly 30 minutes past the court’s own self-imposed deadline. Two justices — Samuel Alito and Clarence Thomas — dissented publicly and at length, with Alito calling the decision “unreasoned” and “remarkable.”
What the Court Actually Decided
A divided Supreme Court indefinitely extended a freeze on strict new restrictions for dispensing mifepristone while an underlying legal fight over the drug plays out. The order provides legal certainty for pharmacies, telehealth companies, and clinicians caught up in the latest battle over accessing the pill.
The ruling pauses a May 1 decision from the U.S. Court of Appeals for the 5th Circuit, based in New Orleans, which had ruled that the Food and Drug Administration must revert to 2022 rules requiring mifepristone to be prescribed and dispensed in person only. That 5th Circuit ruling would have applied to the entire country — not just Louisiana, which bans abortion in nearly all circumstances.
Teleprescribing and mailing of abortion drugs now account for more than 60% of all abortions in the health system. A ruling in Louisiana’s favor would have been the most sweeping restriction on abortion access since the Supreme Court overturned Roe v. Wade in 2022.
Alito’s Dissent: “A Scheme to Undermine Dobbs”
Alito did not hold back. In his dissent, Alito called the majority’s order “unreasoned” and said: “What is at stake is the perpetration of a scheme to undermine our decision in Dobbs v. Jackson Women’s Health Organization — which restored the right of each State to decide how to regulate abortions within its borders.
Thomas, in a separate dissent, argued that mail-order mifepristone violates the Comstock Act — a long-dormant 19th-century law that prohibits mailing “obscene” materials. “I write separately to note that, as Louisiana argued below, it is a criminal offense to ship mifepristone for use in abortions,” Thomas wrote, adding that the drug manufacturers “cannot, in any legally relevant sense, be irreparably harmed by a court order that makes it more difficult for them to commit crimes.
The majority issued no written explanation. That silence — standard practice in emergency orders — left the dissents as the only public reasoning on record.
The FDA Is Absent. The Trump Administration Is Watching.
One of the most striking features of the case is who was not in the room. The FDA, the named defendant in the Louisiana lawsuit, filed no brief to the justices. The Trump administration has not taken a clear public position, with legal analysts suggesting the White House is trying to avoid alienating either base voters who oppose abortion or swing voters who support contraceptive and medication access.
The FDA is conducting a safety review of mifepristone and previously asked a judge to hold off on ruling until that review was complete. Anti-abortion voices accused then-FDA Commissioner Marty Makary of stalling the review before he resigned this week. His temporary replacement has already taken more vocally anti-abortion positions.
That leadership change at the FDA adds another layer of uncertainty. The agency’s next move on the safety review — and whether it accelerates toward restricting the drug — could reshape this legal fight entirely.
What Happens Next
The Supreme Court did not agree to immediately hear the underlying legal arguments in the case, instead sending it back to the 5th Circuit. But the case will likely end up at the Supreme Court again.
After the 5th Circuit’s May 1 ruling, some providers said they would continue offering telemedicine access to abortion medication using a higher-dose misoprostol protocol that does not require mifepristone. Researchers say that method is equally safe and effective, but tends to produce more side effects for patients, including nausea and diarrhea.
| Mifepristone — Where Things Stand | Status |
|---|---|
| Mail/telehealth access | Preserved by Supreme Court order |
| 5th Circuit May 1 ruling | Frozen pending appeal |
| Justices who dissented publicly | Alito, Thomas |
| FDA safety review | Ongoing; no brief filed in this case |
| Louisiana’s argument | Mail access violates Comstock Act, state abortion law |
| Share of abortions via mail/telehealth | More than 60% |
| Case’s next destination | Back to 5th Circuit |
The legal battles over mifepristone will not end here. They will not end at the 5th Circuit either. The only question is how many rounds remain before the Supreme Court is forced to weigh in on the full merits — and whether the FDA’s safety review hands the majority a reason to look at it differently next time.
